Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

Interferon‐α alone vs standard targeted therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.17 [1.03, 1.32]
1 study · 408 participants
Low

Interferon‐α plus bevacizumab vs standard targeted therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.18 [0.85, 1.62]
1 study · 82 participants
Low

Interferon‐α combined with targeted therapies vs standard targeted therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.3 [1.17, 1.45]
1 study · 416 participants
Low